ClinicalTrials.gg
CompletedNCT05197062Updated Apr 27, 2025

A Study of 14C JNJ-67953964 in Healthy Adult Male Participants

A Phase 1 interventional study of 14C-aticaprant in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Mar 2022, 4 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to assess the pharmacokinetic (PK), metabolism, and routes of excretion of aticaprant and its metabolites in excreta and in plasma after a single oral dose 14C-aticaprant in healthy adult male participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy on the basis of physical examination, medical history (screening only), vital signs, and (ECG) performed at screening and admission to the study site on Day -1. Minor abnormalities in ECG, which are not considered to be of clinical significance by the investigator, are acceptable
  • Body weight not less than 50 kilograms (kg) and (BMI; weight [kg]/height\^2 [m\^2]) within the range of 18.0 to 29.9 kilogram per meter square (kg/m\^2) (inclusive)
  • Blood pressure (after the participant is supine for 5 minutes) between 90 millimeters of mercury (mmHg) and 140 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic at screening and Day -1
  • A 12-lead ECG consistent with normal cardiac conduction and function, at screening and Day -1, including: sinus rhythm; pulse rate between 40 and 100 beat per minutes (bpm), extremes included; less than or equal to (\<=) 450 milliseconds (ms) for men; QRS interval of less than (\<) 120 ms; PR interval \< 210 ms; morphology consistent with healthy cardiac conduction and function
  • Non-smokers (not smoked for 3 months prior to screening)

Exclusion criteria

Exclusion Criteria:

  • History of within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin, or malignancy, which is considered cured with minimal risk of recurrence)
  • Known allergies, , or intolerance to aticaprant or its
  • History of (example: in the opinion of the investigator) drug and/or food allergies
  • Participant has presence of left bundle branch block, atrioventricular block (second degree or higher), or a permanent pacemaker or implantable cardioverter defibrillator
  • Anatomical (nasal) abnormalities which may make the placement of the nasoduodenal tube difficult (only for participants with duodenal sampling)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    14C-aticaprant

    Participants in Group A (without duodenal fluid collection) and Group B (with duodenal fluid collection) will receive a single oral dose of 14C-aticaprant on Day 1.

    Drug: 14C-aticaprant

Interventions

  • 14C-aticaprant will be administered orally as capsule on Day 1.

    Also known as: JNJ-67953964

06

What researchers measure

Primary outcomes

  1. Plasma Concentrations of Aticaprant and its Metabolite M3

    Plasma samples will be analyzed to determine concentrations of aticaprant and its Metabolite M3 using a validated, specific, and sensitive liquid chromatography (LC)-mass spectrometry (MS)/MS method.

    Time frame: Up to Day 39

  2. Duodenal Concentrations of Aticaprant and its Metabolite M3

    Duodenal fluid samples will be analyzed to determine concentrations of aticaprant and its Metabolite M3 using a, specific, and sensitive (LC-MS/MS) method.

    Time frame: Pre-dose, 3.75 hour, 4 hour and 5 hour of Day 1

  3. Urine Concentration of Aticaprant and its Metabolites M3

    Urine samples will be analyzed to determine concentrations of aticaprant and its metabolite M3 using a, specific, and sensitive (LC-MS/MS) method.

    Time frame: Pre-dose up to Day 32

  4. Total Radioactivity Concentration of 14C-aticaprant in Whole Blood

    Total radioactivity concentration of 14C-aticaprant in whole blood will be performed via liquid scintillation counting.

    Time frame: Pre-dose up to Day 14

  5. Total Radioactivity Concentration of 14C-aticaprant in Plasma

    Total radioactivity concentration of 14C-aticaprant in plasma will be performed via liquid scintillation counting.

    Time frame: Pre-dose up to Day 14

  6. Total Radioactivity Concentration of 14C-aticaprant in Duodenal Fluid

    Total radioactivity concentration of 14C-aticaprant in duodenal fluid samples will be performed via liquid scintillation counting.

    Time frame: Pre-dose, 3.75 hour, 4 hour and 5 hour of Day 1

  7. Amount of Total Radioactivity of 14C-aticaprant in Urine

    Amount of total radioactivity of 14C-aticaprant in urine will be performed via liquid scintillation counting.

    Time frame: Up to Day 32

  8. Amount of Total Radioactivity of 14C-aticaprant in Feces

    Amount of total radioactivity of 14C-aticaprant in feces will be performed via liquid scintillation counting.

    Time frame: Up to Day 32

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

    Time frame: Up to Day 67

  2. Number of Participants with Clinical Laboratory Abnormalities

    Number of participants with clinical laboratory abnormalities (including serum chemistry, hematology and urinalysis) will be reported.

    Time frame: Up to Day 67

  3. Number of Participants with Electrocardiogram (ECG) Abnormalities

    Number of participants with ECG abnormalities will be reported.

    Time frame: Up to Day 67

  4. Number of Participants with Vital Signs Abnormalities

    Number of participants with vital signs abnormalities (including body temperature, pulse rate, respiratory rate, blood pressure \[systolic and diastolic\]) will be reported.

    Time frame: Up to Day 67

  5. Number of Participants with Physical Examination Abnormalities

    Number of participants with physical examination abnormalities will be reported.

    Time frame: Up to Day 67

07

Study locations

1 site
  • PRA Health Sciences
    Groningen, NZ 9728, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Mar 2022, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2022
First posted
Jan 19, 2022
StartActual
Jan 14, 2022
Primary completionActual
Mar 2, 2022
CompletionActual
Mar 2, 2022
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05197062
Responsible party
Sponsor
First posted
Jan 19, 2022
Start date
Jan 14, 2022
Primary completion
Mar 2, 2022
Completion
Mar 2, 2022
Last update
Apr 27, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aticaprant

Start the discussion